



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/478451/2012

European Medicines Agency decision P/0156/2012

of 25 July 2012

on the acceptance of a modification of an agreed paediatric investigation plan for fosaprepitant (Ivemend), (EMA-000406-PIP01-08-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.



European Medicines Agency decision

P/0156/2012

of 25 July 2012

on the acceptance of a modification of an agreed paediatric investigation plan for fosaprepitant (Ivemend), (EMA-000406-PIP01-08-M03) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/137/2009 issued on 15 July 2009, the decision P/170/2011 issued on 8 July 2011,

Having regard to the application submitted by Merck Sharp & Dohme Ltd. on 23 March 2012 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 8 June 2012, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for fosaprepitant (Ivemend), powder for solution for infusion, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Merck Sharp & Dohme Ltd., Hertford Road, EN11 9BU Hoddesdon (Hertfordshire), United Kingdom.

Done at London, 25 July 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)

EMA/478451/2012

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000406-PIP01-08-M03

Scope of the application

Active substance(s):

Fosaprepitant

Invented name:

Ivemend

Condition(s):

Prevention of nausea and vomiting

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Powder for solution for infusion

Route(s) of administration:

Intravenous use

Name / corporate name of the PIP applicant:

Merck Sharp & Dohme Ltd.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Merck Sharp & Dohme Ltd. submitted to the European Medicines Agency on 23 March 2012 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/137/2009 issued on 15 July 2009, the decision P/170/2011 issued on 8 July 2011.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 16 April 2012.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 8 June 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Prevention of nausea and vomiting

The waiver applies to:

- Newborn infants (from birth to less than 28 days), infants (from 28 days to less than 6 months);
- For powder for solution for infusion , intravenous use;
- On the grounds that the specific medicinal product is likely to be unsafe;
- On the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric Investigation Plan

2.1. Condition: Prevention of nausea and vomiting

2.1.1. Indication(s) targeted by the PIP

Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy in paediatric patients.

Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy in paediatric patients.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Powder for solution for infusion, intravenous use.

2.1.4. Studies

Area	Number of studies	Description
Quality	0	Not applicable.
Non-clinical	2	Study 1: Range-finding juvenile toxicity study in rats (exploratory). Study 2: Juvenile animal toxicity study.
Clinical	1	Study 3: A multi-centre, open-label, 5-part study to evaluate the pharmacokinetics, safety, and tolerability of aprepitant and fosaprepitant dimeglumine in paediatric patients receiving emetogenic chemotherapy.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	No.
Date of completion of the paediatric investigation plan:	By Dec 2013
Deferral for one or more studies contained in the paediatric investigation plan:	No.

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Prevention of nausea and vomiting

Authorised indications:

Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy in adults.

Prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.

EU Number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Content (concentration)	Packaging size
EU/1/07/437/001	Ivemend	115 mg	Powder for solution for infusion	Intravenous use	vial (glass)	10 ml	1 vial
EU/1/07/437/002	Ivemend	115 mg	Powder for solution for infusion	Intravenous use	vial (glass)	10 ml	10 vials
EU/1/07/437/003	Ivemend	150 mg	Powder for solution for infusion	Intravenous use	vial (glass)	10 ml	1 vial
EU/1/07/437/004	Ivemend	150 mg	Powder for solution for infusion	Intravenous use	vial (glass)	10 ml	10 vials